vs

Side-by-side financial comparison of Ispire Technology Inc. (ISPR) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Ispire Technology Inc. is the larger business by last-quarter revenue ($20.3M vs $12.5M, roughly 1.6× Avidity Biosciences, Inc.). Ispire Technology Inc. runs the higher net margin — -32.5% vs -1398.3%, a 1365.8% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -51.5%). Ispire Technology Inc. produced more free cash flow last quarter ($-4.0M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -17.8%).

Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

ISPR vs RNA — Head-to-Head

Bigger by revenue
ISPR
ISPR
1.6× larger
ISPR
$20.3M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+485.5% gap
RNA
434.0%
-51.5%
ISPR
Higher net margin
ISPR
ISPR
1365.8% more per $
ISPR
-32.5%
-1398.3%
RNA
More free cash flow
ISPR
ISPR
$152.8M more FCF
ISPR
$-4.0M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-17.8%
ISPR

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
ISPR
ISPR
RNA
RNA
Revenue
$20.3M
$12.5M
Net Profit
$-6.6M
$-174.4M
Gross Margin
17.1%
Operating Margin
-33.9%
-1513.5%
Net Margin
-32.5%
-1398.3%
Revenue YoY
-51.5%
434.0%
Net Profit YoY
17.4%
-117.0%
EPS (diluted)
$-0.12
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ISPR
ISPR
RNA
RNA
Q4 25
$20.3M
Q3 25
$30.4M
$12.5M
Q2 25
$20.1M
$3.8M
Q1 25
$26.2M
$1.6M
Q4 24
$41.8M
$3.0M
Q3 24
$39.3M
$2.3M
Q2 24
$37.3M
$2.0M
Q1 24
$30.0M
$3.5M
Net Profit
ISPR
ISPR
RNA
RNA
Q4 25
$-6.6M
Q3 25
$-3.3M
$-174.4M
Q2 25
$-14.8M
$-157.3M
Q1 25
$-10.9M
$-115.8M
Q4 24
$-8.0M
$-102.3M
Q3 24
$-5.6M
$-80.4M
Q2 24
$-3.5M
$-70.8M
Q1 24
$-5.9M
$-68.9M
Gross Margin
ISPR
ISPR
RNA
RNA
Q4 25
17.1%
Q3 25
17.0%
Q2 25
12.3%
Q1 25
18.2%
Q4 24
18.5%
Q3 24
19.5%
Q2 24
28.3%
Q1 24
20.4%
Operating Margin
ISPR
ISPR
RNA
RNA
Q4 25
-33.9%
Q3 25
-8.9%
-1513.5%
Q2 25
-72.7%
-4448.7%
Q1 25
-40.4%
-8360.9%
Q4 24
-17.6%
-4069.6%
Q3 24
-13.4%
-4200.9%
Q2 24
-9.2%
-4040.4%
Q1 24
-18.8%
-2178.6%
Net Margin
ISPR
ISPR
RNA
RNA
Q4 25
-32.5%
Q3 25
-10.7%
-1398.3%
Q2 25
-73.4%
-4089.3%
Q1 25
-41.5%
-7360.0%
Q4 24
-19.1%
-3439.5%
Q3 24
-14.2%
-3441.7%
Q2 24
-9.4%
-3461.8%
Q1 24
-19.7%
-1943.4%
EPS (diluted)
ISPR
ISPR
RNA
RNA
Q4 25
$-0.12
Q3 25
$-0.06
$-1.27
Q2 25
$-0.26
$-1.21
Q1 25
$-0.19
$-0.90
Q4 24
$-0.14
$-0.80
Q3 24
$-0.10
$-0.65
Q2 24
$-0.07
$-0.65
Q1 24
$-0.11
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ISPR
ISPR
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$17.6M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$-7.7M
$1.9B
Total Assets
$84.4M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ISPR
ISPR
RNA
RNA
Q4 25
$17.6M
Q3 25
$22.7M
$350.2M
Q2 25
$24.4M
$243.9M
Q1 25
$23.5M
$254.2M
Q4 24
$34.4M
$219.9M
Q3 24
$37.7M
$370.2M
Q2 24
$35.1M
$575.8M
Q1 24
$39.5M
$471.4M
Stockholders' Equity
ISPR
ISPR
RNA
RNA
Q4 25
$-7.7M
Q3 25
$-1.8M
$1.9B
Q2 25
$604.7K
$1.2B
Q1 25
$14.8M
$1.3B
Q4 24
$24.2M
$1.4B
Q3 24
$30.7M
$1.5B
Q2 24
$34.5M
$1.2B
Q1 24
$35.9M
$830.9M
Total Assets
ISPR
ISPR
RNA
RNA
Q4 25
$84.4M
Q3 25
$96.4M
$2.1B
Q2 25
$102.2M
$1.4B
Q1 25
$115.7M
$1.5B
Q4 24
$132.0M
$1.6B
Q3 24
$129.0M
$1.6B
Q2 24
$122.6M
$1.3B
Q1 24
$108.0M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ISPR
ISPR
RNA
RNA
Operating Cash FlowLast quarter
$-4.0M
$-156.2M
Free Cash FlowOCF − Capex
$-4.0M
$-156.9M
FCF MarginFCF / Revenue
-19.9%
-1257.6%
Capex IntensityCapex / Revenue
0.3%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-14.2M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ISPR
ISPR
RNA
RNA
Q4 25
$-4.0M
Q3 25
$-1.2M
$-156.2M
Q2 25
$4.7M
$-199.7M
Q1 25
$-12.5M
$-124.8M
Q4 24
$-3.2M
$-99.9M
Q3 24
$3.6M
$-65.6M
Q2 24
$-1.4M
$-65.0M
Q1 24
$3.4M
$-70.4M
Free Cash Flow
ISPR
ISPR
RNA
RNA
Q4 25
$-4.0M
Q3 25
$-1.2M
$-156.9M
Q2 25
$3.7M
$-203.0M
Q1 25
$-12.7M
$-128.6M
Q4 24
$-3.2M
$-103.8M
Q3 24
$3.3M
$-67.3M
Q2 24
$-2.2M
$-65.5M
Q1 24
$3.3M
$-71.3M
FCF Margin
ISPR
ISPR
RNA
RNA
Q4 25
-19.9%
Q3 25
-3.9%
-1257.6%
Q2 25
18.6%
-5277.1%
Q1 25
-48.4%
-8174.3%
Q4 24
-7.7%
-3491.0%
Q3 24
8.5%
-2881.8%
Q2 24
-5.9%
-3204.6%
Q1 24
10.9%
-2012.3%
Capex Intensity
ISPR
ISPR
RNA
RNA
Q4 25
0.3%
Q3 25
0.0%
5.7%
Q2 25
4.8%
86.9%
Q1 25
0.7%
238.6%
Q4 24
0.1%
131.7%
Q3 24
0.7%
72.9%
Q2 24
2.0%
26.0%
Q1 24
0.3%
25.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons